Patents for Chemicals, Pharmaceuticals, and Biotechnology
Autor Philip W. Grubb, Peter R. Thomsen, Tom Hoxie, Gordon Wrighten Limba Engleză Hardback – 22 dec 2016
Preț: 1293.26 lei
Preț vechi: 1828.87 lei
-29% Nou
Puncte Express: 1940
Preț estimativ în valută:
247.50€ • 257.09$ • 205.59£
247.50€ • 257.09$ • 205.59£
Carte tipărită la comandă
Livrare economică 23-29 ianuarie 25
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9780199684731
ISBN-10: 0199684731
Pagini: 624
Dimensiuni: 165 x 240 x 42 mm
Greutate: 1.08 kg
Ediția:6
Editura: OUP OXFORD
Colecția OUP Oxford
Locul publicării:Oxford, United Kingdom
ISBN-10: 0199684731
Pagini: 624
Dimensiuni: 165 x 240 x 42 mm
Greutate: 1.08 kg
Ediția:6
Editura: OUP OXFORD
Colecția OUP Oxford
Locul publicării:Oxford, United Kingdom
Recenzii
This reviewer agrees with the advertising blurb which states that the book 'will be particularly useful for trainees and new entrants to the patent profession'. It provides a helpful entrée to the field of patenting.
Notă biografică
Philip Grubb is formerly Intellectual Property Counsel of Novartis International AG, and Adjunct Professor of the Franklin Pierce Law Center, Concord, NH (2007-8). Peter R. Thomsen is a Swiss and European Patent Attorney and a CEIPI (University of Strasbourg) tutor. He was elected into the Council of the Institute of Professional Representatives before the European Patent Office (epi) for the period 2011-2014 and is currently working as Global Head IP-Policy and Senior Manager IP-Litigation at Novartis International AG. Tom Hoxie is a Patent Attorney with over 25 years of experience in intellectual property law, and founder of his own law firm, Hoxie & Associates LLC. He has given numerous seminars on patent law to patent attorneys in the United States and Europe and was a tutor in European patent law for the Centre d'Etudes Internationales de la Propriété Industrielle (CEIPI) at the Université de Strasbourg.Gordon Wright is a Consultant and UK and European Patent Attorney at Elkington & Fife LLP. He has nearly 30 years experience in patents, the greater part of which was spent in-house in the pharmaceutical industry.